alpha-cyano-4-hydroxycinnamate has been researched along with Glioblastoma in 1 studies
alpha-cyano-4-hydroxycinnamate: specific inhibitor of pyruvate transport in rat liver mitochondria & human erythrocytes; structure
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, NN | 1 |
| Granja, S | 1 |
| Boni, FI | 1 |
| Ferreira, LMB | 1 |
| Reis, RM | 1 |
| Baltazar, F | 1 |
| Gremião, MPD | 1 |
1 other study available for alpha-cyano-4-hydroxycinnamate and Glioblastoma
| Article | Year |
|---|---|
A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Chitosan; Coumaric | 2020 |